SCHEMBL1970307

SCHEMBL1970307

Cc1ccc(-c2ncncc2C(=O)O)cc1C

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MCL1 Q07820 1/20 0.50
ALDH1A1 P00352 3/20 0.44
ALPL P05186 1/20 0.42
CA9 Q16790 1/20 0.42
XDH P47989 1/20 0.41
SLC22A12 Q96S37 1/20 0.41
HCRTR1 O43613 1/20 0.41
HCRTR2 O43614 1/20 0.41
LDHA P00338 1/20 0.41
KMO O15229 3/20 0.40
AURKA O14965 1/20 0.39
AURKB Q96GD4 1/20 0.39
MEN1 O00255 1/20 0.39
NPC1 O15118 1/20 0.39
LMNA P02545 1/20 0.39
MAPT P10636 1/20 0.39
RAB9A P51151 1/20 0.39
KMT2A Q03164 1/20 0.39
NEK2 P51955 1/20 0.39
CAMKK2 Q96RR4 2/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1972138 0.83 GAA (0.47) MCL1ALDH1A1XDHSLC22A12HCRTR1
SCHEMBL1970072 0.81 KMO (0.50) HCRTR1HCRTR2LDHAKMOMEN1
SCHEMBL1968963 0.79 MCL1 (0.50) MCL1ALDH1A1ALPLCA9XDH
SCHEMBL1967616 0.79 KMO (0.57) XDHSLC22A12HCRTR1HCRTR2KMO
SCHEMBL16806030 0.79 MAPT (0.41) ALDH1A1AURKAMEN1NPC1LMNA
SCHEMBL1968241 0.77 LDHA (0.44) ALDH1A1LDHAMEN1LMNAKMT2A
SCHEMBL1968017 0.76 KDM4E (0.44) ALDH1A1XDHSLC22A12MEN1NPC1
SCHEMBL6490977 0.76 CSNK2A2 (0.49) ALDH1A1XDHSLC22A12KMOMEN1
SCHEMBL10840568 0.76 KMT2A (0.51) ALDH1A1XDHSLC22A12LMNAKMT2A
SCHEMBL26081233 0.76 KDM4E (0.45) ALDH1A1MEN1LMNAMAPTKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-102164896-A Phenethylamide derivatives and their heterocyclic analogues ACTELION PHARMACEUTICALS LTD 2011-08-24 CN claimed
WO-2010044054-A1 PHENETHYLAMIDE DERIVATIVES AND THEIR HETEROCYCLIC ANALOGUES ACTELION PHARMACEUTICALS LTD (CH) 2010-04-22 WO claimed
US-20110212968-A1 PHENETHYLAMIDE DERIVATIVES AND THEIR HETEROCYCLIC ANALOGUES ACTELION PHARMACEUTICALS LTD. (CH) 2011-09-01 US disclosed
CN-102164896-A Phenethylamide derivatives and their heterocyclic analogues ACTELION PHARMACEUTICALS LTD 2011-08-24 CN disclosed
EP-2334643-A1 PHENETHYLAMIDE DERIVATIVES AND THEIR HETEROCYCLIC ANALOGUES Actelion Pharmaceuticals Ltd. (CH) 2011-06-22 EP disclosed
WO-2010044054-A1 PHENETHYLAMIDE DERIVATIVES AND THEIR HETEROCYCLIC ANALOGUES ACTELION PHARMACEUTICALS LTD (CH) 2010-04-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110212968-A1 PHENETHYLAMIDE DERIVATIVES AND THEIR HETEROCYCLIC ANALOGUES HCRTR2, HCRTR1, HRH3 MCL1 3345/4885ALDH1A1 2292/4885ALPL 4866/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.